February 18, 2025
The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, aimed at driving cutting-edge rare disease breakthroughs, announces the appointment of Matthew Anderson, MD, PhD, as co-Director. Dr....
Continue ReadingApril 13, 2016
WILMINGTON, MA, April 13, 2016 – Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development. Through this partnership, Charles River will... Continue Reading
March 15, 2016
2016 Harrington Prize for Innovation in Medicines Recognizes Discovery of Leptin and the Leptin-Mediated Pathway Continue Reading
February 29, 2016
Formed by BioMotiv and Rutgers UniversityCLEVELAND AND NEW BRUNSWICK— FEBRUARY 29, 2016— BioMotiv, a drug development accelerator associated with The Harrington Project, and Rutgers, the State University of New Jersey, are announcing the formation of a new biotechnology startup, Z53 Therapeutics. Z53 Therapeutics aims to... Continue Reading
February 11, 2016
Dr. Jonathan Stamler, director of The Harrington Discovery Institute at University Hospitals in Cleveland, has earned a reputation as a “genius.”“Some people are geniuses,” his fatherâinâlaw Norman Wain said. “Geniuses have a capacity to work.”“He has this sort of infectious personality to want to drive... Continue Reading
January 13, 2016
Cleveland, Ohio – The Harrington Discovery Institute at University Hospitals (UH) in Cleveland, Ohio has announced the 2016 recipients of Harrington Scholar-Innovator Awards. The awards support breakthrough work of physician-scientists whose discovery research shows promise of advancing the standard of care.The Harrington... Continue Reading
January 08, 2016
Cleveland– January 8, 2016 – Dual Therapeutics, LLC (“Dual Therapeutics”) today announced a strategic collaboration with Bristol-Myers Squibb (NYSE: BMY) to advance small molecule compounds for the treatment of cancer and other diseases. Dual Therapeutics’ small-molecule modulators simultaneously block multiple cancer... Continue Reading
May 01, 2015
- 2015 Harrington Scholar-Innovator Continue Reading
May 01, 2015
- 2015 Harrington Scholar-Innovator Continue Reading
May 01, 2015
- 2015 Oxford-Harrington Scholar Continue Reading
May 01, 2015
- 2015 ADDF-Harrington Scholar Continue Reading